GeneMatrix Inc. (KOSDAQ:109820)
2,080.00
+20.00 (0.97%)
At close: Mar 20, 2026
GeneMatrix Market Cap
GeneMatrix has a market cap or net worth of 42.42 billion as of March 20, 2026. Its market cap has decreased by -18.91% in one year.
Market Cap
42.42B
Enterprise Value
n/a
Revenue
4.72B
Ranking
n/a
PE Ratio
n/a
Stock Price
2,080.00
Market Cap Chart
Since November 6, 2009, GeneMatrix's market cap has increased from 33.85B to 42.42B, an increase of 25.32%. That is a compound annual growth rate of 1.39%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 20, 2026 | 42.42B | -15.27% |
| Dec 30, 2025 | 50.07B | -9.74% |
| Dec 30, 2024 | 55.47B | -12.40% |
| Dec 28, 2023 | 63.32B | -23.43% |
| Dec 29, 2022 | 82.69B | -58.54% |
| Dec 30, 2021 | 199.45B | -62.10% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Dx & Vx | 484.76B |
| 3billion | 471.02B |
| GENINUS | 209.12B |
| Cytogen | 123.65B |
| HLB Panagene | 110.95B |
| Green Cross Medical Science | 79.25B |
| Protia | 61.88B |
| Seoulin Bioscience | 57.37B |